BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» Novartis picks up rights to Xoma anti-IL-1 beta assets for $31M, plus debt payment
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Novartis picks up rights to Xoma anti-IL-1 beta assets for $31M, plus debt payment
Aug. 28, 2017
By
Michael Fitzhugh
No Comments
Xoma Corp. is licensing to Novartis AG global commercial rights to its interleukin-1 (IL-1) beta antibody gevokizumab in the wake of Les Laboratories Servier’s decision last year to quit the asset.
BioWorld